# A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer

> **NCT02488564** · PHASE2 · COMPLETED · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS** · enrollment: 49 (actual)

## Conditions studied

- HER-2 Positive Breast Cancer

## Interventions

- **DRUG:** Liposomal doxorubicin
- **DRUG:** Docetaxel
- **DRUG:** Trastuzumab
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT02488564
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-17
- **Primary completion:** 2018-10
- **Final completion:** 2020-03-17
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02488564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02488564, "A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02488564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*